Progression-free survival (PFS) only moderately correlates with overall survival (OS) at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with ...
In this analysis, researchers evaluated whether beta blocker use is associated with improved survival in patients with solid tumors.
Female cancer patients have increased survival but also have a higher risk for serious and adverse side effects from cancer ...
Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and progression-free survival (PFS) in patients with epithelial ovarian cancer They ...
DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet ...
Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results